Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ONAR News: ONAR CEO Claude Zdanow to Present at GenAi Week SV 2025 -
ONAR Holding Corporation
Miami, FL, July 10, 2025 (GLOBE NEWSWIRE) -- ONAR Holding Corporation (OTCQB: ONAR), a fast-growing marketing-technology company and network of performance-driven agencies, today announced its CEO Claude Zdanow will be speaking at GenAi Week Silicon Valley 2025. Zdanow’s keynote presentation 'From SEO to LMO: How AI Language Models Are Rewriting the Rules of AI-Driven Digital Commerce' will take place on July 14th from 12pm – 12:20pm PDT on the Align Stage. GenAI Week SV 2025 will be held at the Santa Clara Convention Center from July 13th to 17th, 2025.
“AI is reshaping how consumers discover and buy products, rendering traditional SEO increasingly ineffective,” said Zdanow. “In my presentation, I’ll explore why Language Model Optimization represents the next critical frontier in AI-driven commerce. I’m looking forward to sharing my perspective and engaging with the exceptional AI leaders attending the event.”
Zdanow’s presentation will explore the fundamental shift from optimizing for search algorithms to optimizing for AI reasoning and recommendation engines. Attendees will gain:
Deep insights into how LLMs evaluate, rank, and recommend products and services
Understanding of the AI-first commerce ecosystem emerging in 2025
Four proven LMO strategies to ensure your brand thrives in AI-mediated transactions
GenAI Week SV 2025 will bring together industry leaders in generative AI and offer a premier platform for networking, knowledge-sharing, and showcasing the latest developments in AI. The event is expected to draw 30,000+ attendees, 400+ speakers, 300+ exhibitors, and 1,000+ VCs.
About ONAR
ONAR (OTCQB: ONAR) is a leading marketing technology company and marketing agency network. The Company’s mission is to power unparalleled marketing services that drive revenue growth through an integrated, AI-driven approach. Committed to honor, candor, and best-in-class results, ONAR's agency network offers a range of digital marketing services including performance marketing & healthcare marketing. ONAR’s agencies focus on servicing middle-market and growth stage companies, and the Company is actively searching for agencies to acquire and become part of the network. Additionally, the Company’s technology incubator, ONAR Labs, is focused on identifying, developing, and commercializing innovative marketing technology solutions. For more information, visit www.onar.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on ONAR's current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy, and financial needs. These statements are not historical facts and are inherently uncertain and outside of ONAR's control. Forward-looking statements include, among other things, statements regarding ONAR's expectations regarding its ability to achieve its financial and strategic goals, including surpassing $100 million in revenue and securing a NASDAQ listing; its ability to expand its client base and market share; and its ability to develop and launch new products and services. Actual results may differ materially from ONAR's expectations and projections due to various risks and uncertainties, including market conditions, competition, the ability to protect intellectual property, the ability to manage growth, changes in laws and regulations, and other factors described in ONAR's filings with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and ONAR undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Media Contact:
Sara Scully
Marketing Manager
ONAR
213-437-3081
IR@onar.com
VTXB has Only 1.6B shares of the FIXED Tiny float and the Maximized Low SS (3.9B/4B shares FIXED OS/AS)!
Buying its peer (BIEL) at its recent high $0.122 = buying VTXB at $0.75582 which is 7558.2 Times of current Ridiculous-Low price $0.0001!
Buying its peer (BIEL) at its most recent high $0.0080 = buying VTXB at $0.0496 which is 496 Times of current Ridiculous-Low price $0.0001!
So, VTXB is Super Undervalued now! Easy to run 100-Bagger+ Quick Rally from current Ridiculous-Low price $0.0001!
VTXB is also at Hyper Oversold status --- from its recent high $0.0951 to current Bottom price $0.0001!
VTXB is Much-Much-Much Cheaper than Thousands of its Same Current-Information-tier or Worse Limited-Information-tier OTC peers, such as BIEL, ATVK, CBLO, SSHT, EBYH, ADHC, and VIZC etc.!
VINC is the Best Investment-Grade OTC-CI-tier stock! It had Very Positive Great News on 06/06/2025 --- see the link below!
https://www.otcmarkets.com/filing/html?id=18534240&guid=Pec-kWqCcmy2B3h
This Long-Expected (from all the shareholders) Exciting Excellent News will trigger a 10-Bagger ~ 30-Bagger Huge Rapid Rally in the coming days/weeks...
We might see the Low Analyst Target $1.400421 before July 16 (Liquidation-Voting Day)! The High Analyst Target will be its most recent high $10.374!
From the latest financial report below of its Same Bio-Tec but DELINQUENT LIMITED-Information-tier OTC peer (TTOO), it has -$0.56 a share HUGE NEGATIVE Book Value and -$12M HUGE NEGATIVE Net Asset or Shareholder's Equity Value plus 28,301,887 shares HUGE OS but was trading at the Highly-Inflated Ridiculous-High price levels $0.056 ~ $0.259 most recently vs. VINC (NON-DELINQUENT CURRENT-Information-tier) has $0.4 a share HUGE POSITIVE Book Value and -$2.1M HUGE POSITIVE Net Asset or Shareholder's Equity Value plus 5,234,277 shares TINY OS but was trading at the Super-Undervalued Ridiculous-Low price levels $0.0417 ~ $0.1 , LOL!
https://www.otcmarkets.com/filing/html?id=17974768&guid=QH0-keX4vAHwwch
VINC is Much-Much-Much Cheaper than Thousands of its Same CI-tier or Worse LI-tier OTC peers, such as TTOO and MAXQ!
$IVDN News: Innovative Designs Delivers Record Sales Growth and Highest Profitability Level to Date for First 6 Months of 2025 With 265% Increase Year-Over-Year
June 17, 2025
https://www.newmediawire.com/news/innovative-designs-delivers-record-sales-growth-and-highest-profitability-level-to-date-for-first-6-months-of-2025-with-265-increase-year-over-year-7080910
$IVDN News: Innovative Designs Delivers Record Sales Growth and Highest Profitability Level to Date for First 6 Months of 2025 With 265% Increase Year-Over-Yearhttps://t.co/mhEYJuGG45 #Profitability #RevenueGrowth #HomeBuilding #Insulation #Construction #Insultex pic.twitter.com/oTsgcXERGK
— Innovative Designs, Inc (Stock: $IVDN) (@riccelli_joseph) June 17, 2025
$IVDN News: Innovative Designs Projects Over 150% Increase in Fiscal Second Quarter Sales Results vs Previous Year, Continuing Multiple Quarters of Profitability
Increasing Recognition of Superior and Patented Evacuated Cell Insulation as the Best Option in Homebuilding Driving Ongoing Record Sales
PITTSBURGH, PA - May 20, 2025 (NEWMEDIAWIRE) - Innovative Designs, Inc. (OTC Pink: IVDN) today is able to project its revenue growth for the fiscal second quarter of 2025, ending on April 30th, will exceed previous expectations and deliver over $750,000 (at least 150% increase over the fiscal 2nd quarter of 2024). This new milestone will continue the Company's profitability, which now spans the last three trailing quarters. For the first 6 months of fiscal 2025 IVDN sales revenue will have already approximately reached the total for all of fiscal 2024. Management expects to file a finalized financial report ahead of the June 15th SEC posting requirement.
Continued demand for Innovative Designs Insultex House Wrap(R) is being driven by new government building codes specifying continuous insulation and exterior R-Value requirements. For new construction, our patented and unique evacuated cell Insultex House Wrap(R), adds an R-6 moisture barrier membrane that does not need additional insulation boards or other support as with other products from competitors. This makes Insultex House Wrap(R), the best overall insulation house wrap choice available on the market today. For full product specifications and details visit: http://www.insultexhousewrap.com.
Randy Kimbler of Insultex(R) Distributor Built Link Solutions, LLC commented, "Due to the sharply increasing interest that the superior Insultex(R) solution is generating, we have recently expanded our marketing campaign into new states which include: Connecticut, Massachusetts, South Dakota, Montana and Maryland. We have also been increasing the size of our sales staff to meet the rising level of inquiries being receiving as the advantages of the Insultex(R) product line are becoming more recognized in the national homebuilding industry. There is no better option for insulation performance and cost effectiveness so we anticipate the market demand to continue to rise, going forward and we will be ready to respond."
Joseph A. Riccelli Jr., CEO of Innovative Designs, stated, "Insultex House Wrap(R) is taking its place as a product of choice by more and more homebuilders and remodelers. The continuing record results in our revenue growth clearly illustrate this trend. We expect to be filing our official fiscal second quarter financial report within the next 30 days with finalized numbers, but at this time, we can confidently project at least the record totals cited above which will put IVDN well on a path to its best year ever in 2025. To support this strong sales growth rate, we are still working to boost "Insultex House Wrap(R) production levels from our US-based facilities in Massachusetts and other locations. Additionally, we are anticipating having IVDN stock uplisted to the higher OTCQX tier in the near term as we have completed all steps necessary for this advancement."
About Innovative Designs, Inc.
Innovative Designs, Inc. manufactures the Insultex(R) House Wrap and Arctic Armor(R) Line, under the "i.d.i.gear" label featuring INSULTEX(R). Patented INSULTEX(R) is the thinnest, lightest and warmest insulator in the market today. For more information, please visit: http://www.insultexhousewrap.com and http://www.idigear.com
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.
CONTACT:
Innovative Designs, Inc.
Joseph A. Riccelli Jr., CEO
412-799-0350
Riccellijjr@insultexhousewrap.com
http://www.insultexhousewrap.com
Built Link Solutions, LLC
Randy Kimbler, Director of Business Development
616-443-3200
RandyK@BuiltLinkSolutions.com
$ACGX News: Alliance Creative Group (ACGX) Releases 2025 Q1 Quarterly Report - Significantly Improved Balance Sheet & Reduced Debt
May 15, 2025
https://www.einpresswire.com/article/812558210/alliance-creative-group-acgx-releases-2025-q1-quarterly-report-significantly-improved-balance-sheet-reduced-debt
$CBLO is lighting up the OTC at just $0.01 — and this isn’t just another subpenny with hype and no substance.We're talking about a company that’s exited shell status, launched a 14MW crypto mining facility, entered a joint venture with CoinEdge for next-gen blockchain lending, and made a strategic investment in Cardano ($ADA) with plans to stack up to 1 million ADA.Low float. Real utility. Growing attention. $CBLO is building something serious in the blockchain space — and at this price, it could still be early.
$IVDN: Over $1 Million in Revenue With Continued Profitability Projected in the First Half of 2025 for High Demand Product in the Homebuilding Sector from Innovative Designs, Inc. (IVDN)
IVDN's Leading Distributor, Built Link Solutions, is Delivering Increasing Order Flow for Superior Evacuated Cell Home Insulation Product
PITTSBURGH, PA - April 1, 2025 (NEWMEDIAWIRE) - Innovative Designs, Inc. (OTC Pink: IVDN) is now able to project that the company will hit another revenue growth milestone, reaching over $1 million in sales revenue for the first two quarters of its fiscal 2025 year which ends on April 30th. This successful trend is also projected to continue the Innovative Designs status as a profitable company which was achieved for the first time at the end of the 2024 fiscal year.
Sharply rising demand for the superior and patented Innovative Designs Insultex House Wrap®, is being fueled by new government building codes calling for continuous insulation and exterior R-Value requirements. For new construction, Insultex House Wrap®, adds an R-6 moisture barrier membrane that does not need additional insulation boards or other support as with other products from our competitors. This makes Insultex House Wrap®, the best overall insulation house wrap choice available on the market today. For full details be sure to visit: http://www.insultexhousewrap.com.
Much of the rapidly growing sales success Innovative Designs is now receiving can be credited to our leading Distributor, Built Link Solutions, LLC. As part of their active and very effective marketing program, the Built Link Solutions team has exhibited at multiple trade show events in the past months, presenting Insultex House Wrap® to a wide range of homebuilding professions and building materials suppliers at every level. Randy Kimbler of Built Link Solutions stated, "We are receiving daily calls and emails from builders and materials suppliers looking for a solution to the new R-5 Continuous Insulation requirement for many states. We can now resolve this increasingly important issue with Insultex House Wrap®".
Joseph A. Riccelli Jr., CEO of Innovative Designs, commented, "We have 2025 off to unprecedented growth in the entire history of our Company. We are extremely pleased with the escalating order flow for our superior performance vacuum cell Insultex House Wrap® product and, of course, must extend our acknowledgement to Built Link Solutions for becoming our leading product distributor. With about one month to go in our fiscal 2nd quarter we are now able to project reaching the impressive $1 million revenue tier for the first half of our fiscal 2025 year and continued profitability for the three trailing quarters. We can also project increased sales and revenue growth in the quarters ahead considering the strong customer response and market trends we see developing. To support this growth, we are moving forward with plans to step up manufacturing and shorten delivery times from our production facilities in Massachusetts and other locations. Everyone on our team is delivering the most positive results for Innovative Designs this year."
About Innovative Designs, Inc.
Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest and warmest insulator in the market today. For more information, please visit: http://www.insultexhousewrap.com and http://www.idigear.com
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.
CONTACT:
Innovative Designs, Inc.
Joseph A. Riccelli Jr., CEO
412-799-0350
Riccellijjr@insultexhousewrap.com
http://www.insultexhousewrap.com
Built Link Solutions, LLC
Randy Kimbler, Director of Business Development
616-443-3200
RandyK@BuiltLinkSolutions.com
MIAMI BEACH, FL / ACCESS Newswire / March 12, 2025 / C2 Blockchain, Inc. (OTC PINK:CBLO) a leader in blockchain innovation, has partnered with CoinEdge (https://pr.report/7sya), a fast-growing cryptocurrency financial services provider, to launch a next-generation crypto lending platform. This joint venture aims to redefine digital asset-backed lending, offering users a seamless way to access liquidity without selling their crypto.
$NRXP News: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Initiated filing of a New Drug Application ("NDA") to the FDA for NRX-100 (IV Ketamine) for the treatment of Suicidal Depression; planned filing of an NDA for Accelerated Approval under Breakthrough Designation and Priority Review of NRX-101 for the treatment of bipolar depression in people at risk of akathisia. Both have anticipated PDUFA dates prior to December 31, 2025
The Company has accepted non-binding potential terms from a commercial pharmaceutical company to license and distribute NRX-100, providing over $300 million in milestones plus tiered double-digit royalties based on net sales
Retained a leading regulatory law firm to file a citizen's petition with the US Food and Drug Administration ("FDA") to remove benzethonium chloride – a toxic preservative -- from presentations of ketamine intended for intravenous use; planned 2Q25 filing of an Abbreviated New Drug Application ("ANDA") for the use of preservative-free ketamine in all current indications
HOPE Therapeutics, a wholly owned subsidiary of NRx, signed non-binding letters of intent to acquire three precision psychiatry centers and is currently completing financial due diligence and definitive agreements. Currently negotiating the terms for the acquisition of six additional centers
The HOPE acquisitions are planned to form the foundation for a national network offering interventional psychiatry services to treat suicidal depression, post-traumatic stress disorder ("PTSD") and related conditions
Received and negotiating a term sheet from a publicly-traded strategic investor currently engaged in manufacturing Transcranial Magnetic Stimulation ("TMS") devices to provide capital in support of expansion of further HOPE clinic acquisitions.
Engaged BTIG as financial advisor for clinic acquisition and capital formation; leading global financial services firm specializing in investment banking, institutional trading, research, and related brokerage services for strategic growth opportunities
Regained compliance with the NASDAQ market value of listed securities ("MVLS") requirement
Substantially reduced operating costs compared to prior year
Management continues to forecast, although no assurances can be given, profitability on a forward-looking run-rate basis by year end 2025
WILMINGTON, Del., March 17, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter and year ended December 31, 2024, and provided a business update.
"Our work in the fourth quarter of 2024 and into 2025 has driven significant advances for our company and investors. We have retired debt that was impeding the launch of HOPE Therapeutics and brought new investors into the Company who are aligned with our objectives. We launched the filing of a New Drug Application for NRX-100 for the treatment of Suicidal Depression: a major milestone for NRx. We also moved NRX-101 toward it's NDA for Accelerated Approval in bipolar depression in patients at risk of akathisia, and made meaningful progress building HOPE's best-in-class network of Interventional Psychiatry Clinics. Additionally, two potential strategic transactions that are under negotiation could further accelerate our progress. These accomplishments advance our mission of preventing and treating suicide: work that is critical to our patients, their families and our country," said Jonathan Javitt, MD, MPH, Chairman, and CEO of NRx Pharmaceuticals. "I would like to thank our team for its dedication and hard work, and thank our shareholders for their ongoing support of our mission to bring hope to life."
Key Research and Development and Corporate Activities
NRX-100 (IV, preservative-free ketamine)
According to the CDC, more than 13 million adults contemplate suicide each year; NRX-100 – IV ketamine for Suicidal Depression - can help address this national crisis.
The Company filed Module 3 (manufacturing) of its New Drug Application ("NDA") for NRX-100 (preservative-free sterile IV ketamine) in a tamper-resistant, diversion resistant packaging presentation in the fourth quarter of 2024. NRX-100 was previously granted Fast Track Designation by FDA in combination with use of NRX-101. Ketamine efficacy data from four clinical trials are intended to support the filing. Three manufacturing lots are now complete, with filed stability data suitable for shelf life exceeding two years at room temperature. The anticipated PDUFA date for this NDA is prior to December 31, 2025.
NRX-100 is poised to address the >$3 billion Suicidal Depression market in the US.
The Company has accepted non-binding potential terms from a commercial pharmaceutical company to license and distribute NRX-100 (preservative-free IV ketamine) that provides for over $300 million in potential milestones plus a tiered double-digit royalty, subject to further due diligence and finalized agreement.
In December 2024 the company demonstrated long term stability and sterility of a patentable formulation of preservative-free ketamine, despite longstanding commercial practice of adding benzethonium chloride as a preservative to commercially supplied ketamine. This preservative is a known caustic and toxic substance that has previously demonstrated corneal neurotoxicity and conjunctival toxicity in patients, and generalized neurotoxicity in the laboratory at microgram concentrations. The concentration in current ketamine preparations is substantially higher, with an extensive body of scientific literature documenting concern. Additionally, chronic administration of ketamine is known to increase the risk of cystitis ( Ref ); the relationship of this adverse event to benzethonium chloride is unknown. Now that a long-term stable and sterile preservative-free formulation is available, the Company is filing a citizens petition to seek removal of benzethonium chloride from the human and veterinary ketamine drug supply.
The Company believes that the preservative-free feature of NRX-100 will be deemed of benefit to patients and is consistent with evolving federal policy on toxic preservatives in the US food and drug supply chain. Therefore, in addition to the NDA designed to add treatment of depression to the current ketamine label, the Company plans to file an Abbreviated New Drug Application ("ANDA") in the second quarter of 2025 for the use of preservative-free ketamine in all currently indicated human and veterinary applications. The Company believes it has met all requirements of the ANDA approval process, has demonstrated manufacturing capacity in excess of one million vials per month, and is prepared to supply the broad ketamine market.
As a next-generation product, the Company has developed a novel, patentable pH neutral formulation of ketamine (designed as HTX-100) based on a proprietary excipient that overcomes ketamine's insolubility, that will be suitable for both intravenous and subcutaneous administration. Initial laboratory lots demonstrate shelf stability and ongoing stability is being assessed. Ketamine in its current commercial presentations cannot be administered subcutaneously because of its high acidic (pH 3.5-4.0) properties, an acidity range that is known to cause pain and skin ulcers. This product is expected to undergo clinical testing in 2025/2026 and be ready for FDA approval in late 2026. Oral forms of ketamine and intranasal racemic ketamine have failed to demonstrate sufficiently stable blood levels to replace intravenous ketamine. However, a ketamine formulation capable of achieving clinical benefit via subcutaneous use – in the manner that diabetes drugs are currently administered – could facilitate far broader clinical use of ketamine to treat life-threatening CNS diseases.
The Company has retained a leading regulatory law firm to file the citizen's petition with the US Food and Drug Administration to remove benzethonium chloride, a known neurotoxic substance, from presentations of ketamine intended for intravenous use. The Company believes that the preservative-free feature of NRX-100 will be deemed of benefit to patients because of the known toxicity of benzethonium chloride in current generic products.
NRX-101 (oral D-cycloserine/lurasidone)
Bipolar depression affects approximately seven million people in the US. Current treatment options all carry the risk of suicide and akathisia, a side-effect of serotonin active antidepressants which is closely related to suicide. People with bipolar depression and akathisia or suicidality are at imminent risk of self-harm. These patients need better treatment options urgently.
The Company announced its intention to file an NDA for Accelerated Approval under Breakthrough Designation and Priority Review of NRX-101 for the treatment of bipolar depression in people at risk of akathisia, based on the Phase 2b/3 and STABIL-B data. Three manufacturing lots are now complete with more than 12 months of room temperature shelf-stability. The anticipated PDUFA date for this application is prior to December 31, 2025.
The Company estimates that the market for the initial indication is over $2 billion, while the broad bipolar market could exceed $5 billion.
HOPE Therapeutics
HOPE Therapeutics, a wholly owned subsidiary of NRx Pharmaceuticals, is developing a new clinical paradigm for the treatment of depression, PTSD, obsessive-compulsive disorder, and related CNS conditions. While there is clinical evidence that NMDA-targeted drugs such as NRX-100 and NRX-101 have the potential to offer clinical benefit, many patients additionally require neuromodulatory techniques, such as Transcranial Magnetic Stimulation ("TMS"), digital therapeutics, traditional psychotherapy and medication management to achieve long-term remission from suicidal depression and PTSD. Despite the proliferation of "ketamine clinics" in the US, few psychiatrist-led entities are successful in offering a comprehensive solution to patients and families.
During the second half of 2024, the Company began outlining the plan for HOPE Therapeutics as a national and ultimately international network of Interventional Psychiatry centers that will combine NMDA-targeted and future psychedelic drugs with neuroplastic treatments in an integrated and reproducible manner. The business model for HOPE Therapeutics is similar to that of leading national dialysis providers, companies that were instrumental in making kidney dialysis reliable and reproducible in a manner that transformed the industry and routinely trade at double digit P/E multiples.
In 2024, the Company announced a non-binding Letter of Intent to acquire Kadima, LLC, a pioneering interventional psychiatry clinic in La Jolla, CA. Kadima's founder, Dr. David Feifel agreed to serve as HOPE's Chief Medical Innovation Officer post-acquisition. He is one of the first academic psychiatrists to move ketamine and TMS therapy to the community care model and was recently featured on Dr. Sanjay Gupta's broadcast entitled "The Wild West of Ketamine Treatment" as an advocate for how ketamine therapy can be delivered reliably and responsibly. Link: Wild West of Ketamine.
Subsequent to the Kadima commitment, the Company has, or anticipates, contracting to acquire and/or partner with eight facilities in Florida, aiming for 15-20 facilities in Florida by year-end 2025.
The clinical centers that are being incorporated in the 2025 acquisition program are currently operating and profitable centers that the Company believes can experience substantial revenue growth through the addition of a broader array of comprehensive services. Management estimates that the acquisition of 20 clinic networks, each with current revenue of approximately $5 million will be required to meet its 2025 growth target.
Financings
The Company has consummated a series of financing agreements with an institutional investor for up to $16.3 million in debt capital, for which we closed on $10.9 million in 2024 and subsequently closed $8.5 million in a combination of convertible debt and an above-market common stock and warrant offering in January 2025. Subsequently, we terminated a planned $2 million investment from a smaller fund with less favorable terms.
The Company has also received and is currently negotiating a term sheet with a publicly-traded entity engaged in the manufacture of FDA-cleared devices for Transcranial Magnetic Stimulation to provide acquisition capital to support the expansion of HOPE Therapeutics clinics. In addition, it is negotiating with several commercial lenders to support expansion of HOPE clinics with standard commercial loans. Although business plans are subject to change, assuming consummation of the financings on terms currently contemplated by management, the Company would achieve its objective of financing less than 50% of the proposed acquisition costs, thereby enabling the Company to optimize its cost of acquisition capital as it expands the HOPE clinic network.
Our current financing activities are intended to supplant the previously announced equity investment in HOPE on more favorable terms.
Financial Results for the Quarter and Year Ended December 31, 2024
For the three months ended December 31, 2024, NRx Pharmaceuticals reduced its loss from operations by approximately $2.0 million to $2.4 million from $4.4 million in the fourth quarter of 2023, representing nearly a 45% improvement quarter over quarter primarily driven by lower research and development costs and a settlement gain, which were partially offset by an increase in general and administrative expense. For the three months ended December 31, 2024, research and development expense decreased by approximately $1.5 million to $1.0 million as compared to $2.5 million during the fourth quarter ended December 31, 2023. The $1.5 million decrease is primarily related to a decrease in clinical trial and development expense due to the conclusion of the phase 2b/3 study for NRX-101. Finally, general and administrative expense for the three month period ended December 31, 2024 increased by approximately $0.7 million to $2.6 million as compared to approximately $1.9 million for the three month period ended December 31, 2023, which was primarily driven by higher consulting fees related to the potential acquisition of several psychiatry clinics in support of the growth model for HOPE Therapeutics.
For the year ended December 31, 2024, NRx Pharmaceuticals reduced its loss from operations by approximately $9.3 million, or 33.5%, to $18.5 million from $27.8 million for the year ended December 31, 2023, which was primarily driven by a decrease in research and development expense. For the year ended December 31, 2024, research and development expense decreased by approximately $7.2 million, or 53.6%, to $6.2 million as compared to $13.4 million for the year ended December 31, 2023 primarily driven by a decrease in clinical trial and development expense due to the conclusion of the phase 2b/3 study for NRX-101. Finally, general and administrative expense for the year ended December 31, 2024 decreased by approximately $0.7 million to $13.5 million as compared to $14.2 million for the year ended December 31, 2023 primarily driven by a reduction in insurance and employee costs, and partially offset by an increase in consulting fees related to the potential acquisition of several psychiatry clinics in support of the growth model for HOPE Therapeutics.
As of December 31, 2024, we had approximately $1.4 million in cash and cash equivalents. As noted above, in January 2025, the Company completed two financings with aggregate gross proceeds of approximately $8.5 million. Management believes that current available cash resources will be sufficient to support ongoing operations through at least the end of 2025.
NRx continues to implement operational efficiencies to extend cash runway and maintain focus on our path to generating revenue and value for our shareholders.
Please see detailed financials on our Form 10-K, filed with the SEC and available on our website.
Conference Call and Webcast Details
A live webcast of the conference call will be available on the Company's website at 8:30 a.m. ET Monday March 17, 2025, at https://ir.nrxpharma.com/events. An archive of the webcast will be available on the Company's website for 30 days. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically 1-800-717-1738 or internationally 1-646-307-1865.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a development stage healthcare delivery company that intends to develop a best-in-class network of interventional psychiatry clinics to offer ketamine transcranial magnetics stimulation (TMS) and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including risks arising from uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, HOPE Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund such acquisitions, and the Company's ability to spin-off HOPE Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
https://c212.net/c/img/favicon.png?sn=CL42170&sd=2025-03-17 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-corporate-update-302402666.html
SOURCE NRx Pharmaceuticals, Inc.
$IVDN (16 Million Float): Innovative Designs, Inc. Reaches Profitability for First Time by Reporting of Record Sales Results in Fiscal Year 2024, Delivering Almost 300% Revenue Increase vs. Previous Year
Sales of Superior Evacuated Cell Home Insulation Continue to Surge Into the Fiscal First Quarter for 2025
PITTSBURGH, PA - March 3, 2025 (NEWMEDIAWIRE) - Innovative Designs, Inc. (OTC Pink: IVDN) is extremely pleased to report that the Company has now achieved the key milestone of reaching profitability on the record setting revenue results of its 2024 fiscal year. With the filing of our 10K Annual Statement for the fiscal year ending on October 31, 2024 just posted, IVDN has reported that sales revenues increased to $1,382,733 vs. $347,763 for the 2023 fiscal year. This rapid growth translates to a 298% increase in sales, mostly attributable to the rising demand for our unmatched Evacuated (Vacuum) Cell R-6 Insultex House Wrap.
Fiscal fourth quarter sales were even stronger than we anticipated when we issued our projection in December for a year-end total at $1.2 million. Robust sales are currently continuing in the first half of fiscal 2025. We are working on the largest backorder level for Insultex House Wrap® that the Company has ever experienced and making progress with our suppliers to accelerate product production rates.
Sales of Insultex House Wrap® are now benefiting from new government building codes calling for continuous insulation and exterior R-Value requirements. Insultex House Wrap® is starting to be recognized as the very best option to satisfy the new requirements in terms of performance, cost effectiveness and ease of installation. Insultex House Wrap delivers its advantages thanks to its patented vacuum cell structure design. No other product on the market today offers a vacuum cell structure. A vacuum is the best thermal insulation possible and only Insultex® incorporates countless evacuated cells. Insultex® also provides a moisture barrier and other key benefits. The result is a substantial savings for new construction, adding an R-6 moisture barrier membrane that does not need additional insulation boards or other support as with other available choices from competitors.
Joseph A. Riccelli Jr., the new CEO of Innovative Designs, stated, "We have entered a new and much more rewarding stage of our business as demonstrated by the unprecedented sales results reported in our fiscal 2024 year-end financial report that has just been filed. Reaching the turning point of becoming a profitable company is a great achievement that everyone on our team has worked hard at for many years. With the growing success of the superior Insultex House Wrap® product line, Innovative Designs is positioned to continue building on the financial success we have now reached throughout 2025 and beyond. I am looking forward to arranging IVDN shareholder's conference in the near future to further expand on the reasons for our success, and plans to increase production to meet the rising demand. Additionally, we will be looking into expanding our marketing and sales options for the IDI Gear Insultex® clothing lines. Stay tuned for details on the scheduling of this upcoming IVDN shareholder's conference soon."
About Innovative Designs, Inc.
Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest and warmest insulator in the market today. For more information, please visit: http://www.insultexhousewrap.com and http://www.idigear.com
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.
CONTACT:
Innovative Designs, Inc.
Joseph A. Riccelli Jr., CEO
412-799-0350
riccellijjr@insultexhousewrap.com
http://www.insultexhousewrap.com
$ASII News: Accredited Solutions, Inc. (OTC: ASII) Engages Partner Capital Group, LLC (PartnerCap) to Explore Strategic Alternatives to Maximize Shareholder Value
NEW YORK, NY - March 12, 2025 (NEWMEDIAWIRE) - Accredited Solutions, Inc. (OTC: ASII) ("Accredited Solutions" or the "Company"), a technology-driven operating company focused on strategic fintech, blockchain, and digital assets, is pleased to announce the signing of a Memorandum of Understanding (MOU) to acquire ItsBChain LLC, a blockchain-based subsidiary, from iQSTEL Inc. (OTCQX: IQST). This acquisition aligns with ASII's long-term strategy to expand its presence in blockchain-powered fintech solutions, digital transactions, and payment processing ecosystems.
The acquisition of ItsBChain will enable ASII to leverage blockchain technology in new and innovative ways within the digital finance sector. The integration of ItsBChain's expertise in the telecommunications blockchain market with ASII's growing e-gift card and prepaid financial services portfolio creates significant synergies. Blockchain applications in telecom have proven highly effective in securing transactions, reducing fraud, and improving operational efficiencies. ASII plans to extend these advantages to its digital payment solutions, ensuring enhanced security, transparency, and efficiency for its growing network of partners and customers.
"We are thrilled to welcome ItsBChain to the Accredited Solutions family," said Eduardo Brito, CEO of Accredited Solutions, Inc. "While the market has yet to fully recognize the value of our GlobeTopper acquisition, we remain confident in our vision and long-term growth strategy. The addition of ItsBChain positions us to accelerate our development of blockchain-based payment systems, particularly in the B2B segment, providing secure, efficient, and scalable fintech solutions.
ItsBChain's platform has strong synergy with e-gift payment systems, which not only creates new revenue streams but also significantly reduces transaction costs. Our ambition to become a global leader in fintech payments is driven by the fact that blockchain technology represents the future of payments, and we intend to be at the forefront of this transformation. The synergies from this acquisition will cut our time-to-market by at least 70%, giving us a substantial competitive advantage.
We remain committed to exploring every opportunity to maximize shareholder value, including strategic mergers, partnerships, and new investment initiatives. We deeply appreciate the continued trust and support of our shareholders as we execute our vision."
The definitive Purchase Agreement for ItsBChain is expected to be executed no later than July 1, 2025. ASII is committed to integrating blockchain technology into its financial products and services, reinforcing its leadership in the digital payment sector with enterprise level corporations, incumbent telco operators and premier online retailers.
About Accredited Solutions, Inc.
Accredited Solutions, Inc. (OTC: ASII) is a technology-focused operating company focused on fintech businesses and fintech enterprise solutions, blockchain, and digital payments. Through strategic investments and acquisitions, the Company aims to provide long-term value to its shareholders and advance the future of digital financial services.
For more information, visit: www.diamondcreekwater.com
About ItsBChain
ItsBChain is a blockchain-based technology company specializing in applications for the telecommunications industry. By leveraging blockchain to enhance transaction security, efficiency, and automation, ItsBChain has positioned itself as a leader in blockchain-powered solutions. Its technology is now being adapted to digital financial services, enabling secure and seamless transactions for global markets.
For more information, visit: www.itsbchain.com
About Globetopper
Globetopper is a leading provider of digital transaction solutions, offering a vast portfolio of prepaid financial products, including gift cards, event tickets, cryptocurrency services, and remittance solutions. With access to over 2,700 brands across 65 countries, Globetopper empowers businesses with streamlined solutions for digital payments and rewards programs.
For more information, visit www.globetopper.com
Forward-Looking Statements
This press release contains forward-looking statements that reflect management's expectations regarding future performance. These statements involve risks and uncertainties, and actual results may differ materially. Accredited Solutions, Inc. undertakes no obligation to update any forward-looking statements in this release.
Investor Relations Contact: Accredited Solutions, Inc.
Investor Relations
info@diamondcreekwater.com
View the original release on www.newmediawire.com
$HHSE:..Hannover-House - Status-Update for Shareholders
Friday, January 31, 2025
(Click on link to view photos)
http://hannoverhousemovies.blogspot.com/2025/01/hannover-house-status-update-for.html
Greetings HHSE Friends & Followers - So many exciting things in motion at this time! As requested by some HHSE Longs - here's a quick recap of key items and projects:
1). TRUMP BOOK - Author Barr McClellan asked to add new material in order to cover the historic Inaugural week, plus "Promises Made, Promises Kept" (delivery on campaign pledges), as well as a recap summary chapter called "American Manifesto." These changes and additions will enhance the newsworthiness and shelf-life of the book - elevating it to a more lasting historical record. There will be about a 3-week delay in both the e-book and hardcover editions.... but in the scope of long-term values, we felt that this was a modest delay for a longer-term gain. Meanwhile PRESALES are ASTOUNDING!
2). UNHOLY SONG - This is turning into a MAJOR SURPRISE HIT for HHSE. This low-budget horror thriller is the first title under our newly resurrected "releasing brand" of HEMDALE (the multi-Oscar winning indie studio where Hannover House CEO Eric Parkinson was previously CEO). The teaser trailer has already generated over 7-million total views (mostly via "X" posts and boosted ads) - which is a terrific sign of consumer interest. The film opens in theatres Feb. 28. FOR THE FIRST TIME EVER for a Hannover House release, Fandango and Rotten Tomatoes have ALREADY launched the title page... a full four weeks prior to the film's release! Watch for some jaw-dropping PUBLICITY over the next few weeks... we won't tell you what to watch for in advance.. we'll just SHOW YOU with the photos and video links!
3). HHSE UPLIST - At long last, we are filing the application to uplist to the OTC: QB. Our plan to do this in January was not met, but our commitment remains. There have been some issues to resolve including the refiling of some prior years 1120 corporate tax returns. But we are close to completion, and look forward to the days in which high-volume traders will step-up to support the HHSE stock growth.
4). WILDFIRE - As stated last week, the final theatrical mixing and mastering was completed in Los Angeles... and the film is presently in "delivery mode" to turn this asset into positive cash flow. Some HHSE Longs asked for an explanation of how a Special Purpose Entity such as SNOWY MORNING, INC. is related to a parent organization such as HHSE - and how the transference and capitalization of the balance sheet asset works? We realize that none of our HHSE shareholders (and none of the chat-room posters) have ever actually produced a movie, so this logistics question is understandably an unknown to non-industry professionals. But every major studio and distributor involved in feature productions uses "SPE" Special Purpose Entities for the physical production of features. This is an important step for both signatory status to guilds, as well as for arm's-length protection of the affiliate studio from any liens or liabilities that sometimes occur with feature productions. Once a film is completed and cleared, the asset is moved to the studio owner / distributor.
5). OTHER BIG STUFF - We are preparing for the production shoot of INDIAN TERRITORY - as well as in Pre-Production (in Malta) with TEMPUS PORTA, and a privately funded Native American comedy, HARD TIMES IN T-TOWN. The company is also "almost" finished with the production of NATIVE FABLES - and will have this fully ready in May for the CANNES FILM FESTIVAL (including one of the segments in the short-film showcase competition!).
Last but not least... the MYFLIX Streaming Service is positioned to LAUNCH... we have been awaiting FINANCIAL RESOURCES to assure a success. With deliveries now commencing for WILDFIRE - as well as TRUMP book presales strong and ticket demand for UNHOLY SONG strong - we feel the company will be well-positioned to self-finance the MYFLIX launch in the coming months!
$HHSE partnering-with $DJT...MASSIVE-UPSIDE for BOTH companies:
https://www.otcmarkets.com/otcapi/company/financial-report/419415/content
a). TRUMP MEDIA & TECHNOLOGIES GROUP – In respect of access provided to Barr McClellan and
Hannover House to key Trump campaign operatives – as well as in consideration of a major
promotional campaign to occur with the new Barr McClellan book via “Truth Social” (and national TV
media outreach) in addition to a paid support campaign, the Board approved the issuance of five
million (5,000,000) common stock shares of Hannover House, Inc. (OTC: HHSE), said shares upon
issuance to be temporarily restricted from sale under Rule 144.
TRUMP-EFFECT==$HHSE ready to EXPLODE to the upside. They are partnered with Trump Media ($DJT) on the "Trump-Book" AMERICAN MANIFESTO.
Thanks to all HHSE longs who stuck it out during the tough times. BIG rewards are finally coming, mainly due to the CEO's HARD WORK and TENACITY, navigating through the obstacles along the way, on the road to achieving Mega-SUCCESS.
Time for longs to PROUDLY spread the word on social media and any Trump-related message boards. Our GEM is about-to-be-discovered by the general market, and in a BIG way. Anticipated run = 1,000%, 5,000%, 10,000%....who knows? The Sky's the Limit. Incredible GROWTH ahead.
Place your Pre-Order of the book using link below. Order multiple copies for family and friends (as gifts). Help $HHSE make $million$ from this book, ahead of the imminent Corporate Filings (audits and uplist to OTCQB) and many other announcements like MAJOR movies/productions and their MYFLIX streaming service.
https://www.einpresswire.com/article/771257686/best-selling-author-barr-mcclellan-reveals-campaign-insights-and-strategies-for-trump-victory-in-2024-election
https://www.amazon.com/dp/B0DR84YM8H
$HNOI News: HNO International Secures $10 Million Hydrogen Offtake Agreement with Texas-Based Mobility Company
HOUSTON, Jan. 30, 2025 /PRNewswire/ -- HNO International (OTC: HNOI) is excited to announce a hydrogen offtake agreement with a Texas-based company supporting zero-emission mobility. Under the agreement, HNO will supply hydrogen from its 1.25 MW Scalable Hydrogen Energy Platform (SHEP™), which produces up to 500 kilograms of clean hydrogen daily.
This hydrogen will power the customer's fleet of Class 8 hydrogen fuel cell vehicles (FCEVs), ensuring efficient and sustainable long-haul transportation. The agreement also integrates HNOI's Compact Hydrogen Refueling System (CHRS™) for refueling support. With room for expansion, HNOI is projecting to reach nearly $10 million in multi-year contracts as HNOI rapidly scales hydrogen production within the first year of operation.
"This agreement highlights the growing demand for clean hydrogen fuel in heavy-duty transportation," said Don Owens, founder and CEO of HNO International. "Our SHEP system and CHRS refueling stations provide reliable, scalable solutions for long-haul operations, helping reduce the environmental impact of freight mobility. We're excited to support this effort and look forward to expanding our production capacity to meet rising demand."
The Texas-based company, a leader in zero-emission mobility, is at the forefront of using hydrogen to decarbonize transportation. Their adoption of hydrogen fuel cell technology supports both environmental sustainability and business growth by offering a viable alternative to diesel without compromising operational efficiency.
About HNO International
HNO International (HNOI) is a company specializing in the design, integration, and development of hydrogen-based energy technologies. With over 15 years of experience in hydrogen production, HNOI is on a mission to help lead the renewable energy transition by making energy accessible to businesses and communities. Their solutions, the Scalable Hydrogen Energy Platform (SHEP™) and the Compact Hydrogen Refueling Station (CHRS™), are setting new standards for hydrogen production.
Forward-Looking Statements
This news release contains "forward-looking statements" which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as "anticipate", "seek", intend", "believe", "estimate", "plan", or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K, our quarterly reports on Form 10-Q and other periodic reports filed from time to time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.
https://c212.net/c/img/favicon.png?sn=LA08011&sd=2025-01-30 View original content to download multimedia:https://www.prnewswire.com/news-releases/hno-international-secures-10-million-hydrogen-offtake-agreement-with-texas-based-mobility-company-302364038.html
SOURCE HNO International
$SGBX News: Safe & Green Holdings Announces Equity Line of Credit with Alumni Capital to Accelerate Growth through Shareholder-Friendly Funding Mechanism
MIAMI, FL, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Safe & Green Holdings Corp. (NASDAQ: SGBX) (“Safe & Green Holdings” or the “Company”), a leading developer, designer, and fabricator of modular structures, today announced it has entered into a Securities Purchase Agreement with Alumni Capital LP, establishing an equity line of credit (ELOC). This agreement provides the Company with a flexible funding mechanism to support its strategic growth initiatives while minimizing dilution to existing shareholders.
The funding aligns with Safe & Green's commitment to utilizing capital in a prudent manner, with a focus on highly accretive projects that drive long-term shareholder value. The structure of the ELOC ensures that the Company retains full control over the timing and amount of any equity sales, thereby providing financial stability and strategic flexibility.
Michael McLaren, Chief Executive Officer of Safe & Green Holdings, commented, “This agreement with Alumni Capital represents a key milestone in our growth strategy. It is designed with the best interests of our shareholders in mind, offering us the ability to access capital efficiently while mitigating dilution. We are grateful for the strong support and confidence from Alumni Capital following their extensive due diligence. This funding positions us to accelerate the execution of our strategic initiatives and deliver meaningful value to our shareholders.”
Tricia Kaelin, Chief Financial Officer of Safe & Green Holdings, stated, “We plan to leverage the proceeds from the ELOC to advance our growth agenda, including expansion into new markets, development of high-impact projects, and enhancement of operational efficiencies. Moreover, we remain committed to maintaining a balance between growth, financial discipline, and shareholder interests.”
Ashkan Mapar, Portfolio Manager and General Partner at Alumni Capital, added, “We are pleased to partner with Safe & Green Holdings as they continue to innovate and grow. This agreement reflects our confidence in the Company's vision and management team, and we look forward to supporting their efforts to drive sustainable value creation.”
The flexibility provided by this ELOC allows the Company to align its capital needs with market conditions and operational priorities. Through a disciplined approach, Safe & Green Holdings seeks to deploy capital in areas that maximize returns and strengthen the Company’s market position.
Additional details about the transaction are available in the Company’s Form 8-K that has been filed with the Securities and Exchange Commission.
About Safe & Green Holdings Corp.
Safe & Green Holdings Corp., a leading modular solutions company, operates under core capabilities which include the development, design, and fabrication of modular structures, meeting the demand for safe and green solutions across various industries. The firm supports third-party and in-house developers, architects, builders, and owners in achieving faster execution, greener construction, and buildings of higher value. For more information, visit https://www.safeandgreenholdings.com/ and follow us at @SGHcorp on Twitter.
Safe Harbor Statement
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to successfully satisfy all of the conditions in the Securities Purchase Agreement, the Company’s ability to successfully file a registration statement to register the resale of shares to be purchased by Alumni Capital LP via the Securities Purchase Agreement, the Company’s ability to successfully execute its business plans, the effect of government regulation, the Company’s ability to maintain compliance with the NASDAQ listing requirements, and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020
sgbx@crescendo-ir.com
https://www.globenewswire.com/newsroom/ti?nf=OTM0NzkxOSM2NzIxMTY1IzUwMDEyMTA5NQ==
https://ml.globenewswire.com/media/ZDUzNDFjNTUtMThjYy00Zjc4LWIwMWMtNTZkZDE3N2JjYTliLTUwMDEyMTA5NQ==/tiny/Safe-Green-Holdings-Corp-.png
Source: Safe & Green Holdings Corp.
$ASII News: GlobeTopper Achieves $39.5M in 2024 Revenue, Driven by Strong Q4 Performance
NEW YORK - January 22, 2025 (NEWMEDIAWIRE) - Accredited Solutions, Inc. (OTC: ASII) ("Accredited Solutions" or the "Company"), parent company of Diamond Creek, is thrilled to announce that its wholly-owned subsidiary, GlobeTopper, achieved an outstanding $39.5 million in revenue for 2024, driven by an exceptional fourth quarter, including $4.3 million in December revenue alone.
GlobeTopper, a leader in the B2B digital gift card industry, continues to outperform market expectations by capitalizing on the growing global demand for digital gifting solutions. The company's innovative platform and strategic partnerships with rewards programs, e-commerce platforms, and fintech companies have made GlobeTopper a trusted provider for businesses worldwide, offering seamless access to over 2,700 brands across 65 countries.
Eduardo Brito, CEO of Accredited Solutions, Inc., commented on GlobeTopper's record-breaking performance: "GlobeTopper's exceptional fourth-quarter results reflect the strength of our platform and the effectiveness of our growth strategy. Surpassing $39 million in 2024 revenue is a milestone that positions us as a market leader. With this momentum, we're targeting even greater achievements in 2025, projecting to surpassing $60 million in annual revenue through continued innovation and expansion."
An Extraordinary Year for GlobeTopper
GlobeTopper's success in 2024 highlights its ability to address the evolving needs of the digital economy. With consistent growth throughout the year, capped by an extraordinary fourth quarter, GlobeTopper is well-positioned for continued success in the fintech and e-gifting sectors.
About GlobeTopper
GlobeTopper simplifies digital gift card distribution for businesses, offering a robust platform that enables access to a vast portfolio of e-gift cards from leading global retailers. Its innovative solutions are trusted by rewards programs, e-commerce platforms, and fintech companies to streamline gifting and reward strategies.
About Accredited Solutions, Inc.
Accredited Solutions (OTC: ASII) is a diversified holding company focused on acquiring and scaling innovative, technology-driven businesses. Through subsidiaries like GlobeTopper, Accredited Solutions delivers long-term growth and sustainable value to its shareholders.
Contact Information
Accredited Solutions, Inc.
info@accreditedsolutions.com
www.globetopper.com
www.diamondcreekwater.com
Follow Us on Social Media:
Twitter: @asii_Inc
View the original release on www.newmediawire.com
$RELT News: ONAR Announces ONAR LABS and Commercialization of Proprietary AI Marketing Platform Already Generating Results Across $200M+ in Cumulative Client Revenue
LOS ANGELES, Jan. 22, 2025 /PRNewswire/ -- ONAR (OTCQB: RELT) today announced the launch of ONAR Labs, the company's pioneering technology incubator, and unveiled its first product offering - Cortex, an AI-powered marketing intelligence platform that has been powering the company's agency network, was developed by Storia, and will become available to companies via subscription.
ONAR Labs, established as the company's dedicated innovation hub, will focus on developing and commercializing proprietary marketing technology solutions that have been battle-tested across ONAR's network of agencies. The launch of Cortex marks the first of several planned technology releases aimed at transforming how businesses leverage AI for marketing success.
"Cortex represents years of development and refinement across our agency portfolio," said Claude Zdanow, CEO of ONAR. "What began as an internal tool that drove exceptional results for our clients is now evolving into a commercial platform that will help enterprises remove marketing uncertainty and drive measurable growth through AI-powered intelligence."
Cortex's capabilities include:
Unified Performance Analytics: Real-time monitoring of cross-channel marketing KPIs with automated insights and alerts.
AI-Driven Marketing Forecasting: Predictive modeling that helps businesses anticipate performance trends and optimize campaign strategies.
Intelligent Attribution Modeling: Leverages technology that tracks and analyzes customer journeys across all marketing touchpoints, providing granular attribution insights that show the true impact of every marketing dollar spent - from first click to final conversion.
Multi-Channel Integration: Seamless connection with major platforms, including Google Ads, Meta, TikTok, LinkedIn, Pinterest, and other essential marketing tools.
The platform, which has been integral to the success of ONAR's agency network, and pioneered by ONAR's Storia agency, will be offered as a subscription service with tiered pricing based on business size and needs.
"Having leveraged Cortex's capabilities across our client portfolio, we've seen firsthand how AI-driven marketing intelligence can transform campaign performance," said Chris Becker, President of ONAR. "AI and machine learning is allowing us to unify data, predict trends, and automate insights at scale. It has been a game-changer for our team and clients."
ONAR Labs will operate as a dedicated division within ONAR, focused on identifying, developing, and commercializing innovative marketing technology solutions. The division will be staffed by a team of data scientists, engineers, and industry experts working alongside ONAR's agency professionals to ensure real-world applicability and impact.
"The launch of ONAR Labs and Cortex represents a significant milestone in our company's evolution," added Zdanow. "By commercializing our proprietary technology, we're not only creating a new revenue stream but also helping businesses of all sizes access enterprise-grade marketing intelligence tools that have been proven across our network."
Visit onar.com/labs for updates.
About ONAR
ONAR (OTCQB: RELT) is a dynamic marketing and business solutions network, currently publicly traded as Reliant Holdings, Inc. with plans to become Onar Holding Corporation in the near future. ONAR's mission is to provide unparalleled service through an integrated, AI-driven approach, leveraging its diverse brand family's strengths. Committed to honor, candor, and best-in-class results, ONAR aims to lead the industry by example, ensuring every client relationship is deeply rooted in trust and excellence.
ONAR has nearly 50 employees across five continents, and it is aggressively expanding its team to support the company's growth and acquisition pipeline. Its agencies service over 45 clients across various industries:
Performance Marketing & SEO: Our high-touch performance marketing agency, Storia, specializes in brand growth, data-driven excellence, and paid advertising.
Full-Service Healthcare Marketing: Partnering with healthcare professionals, Of Kos provides the best possible patient experience and strives to revolutionize the standard of care.
Experiential Marketing & Events: CHALK is an experiential marketing powerhouse of event architects who turn bold ideas into unforgettable reality, designing events that dare to defy the ordinary.
ONAR's network of agencies focuses on servicing companies ranging from $50M to $1B+ in revenue, and ONAR is actively searching for agencies to acquire and become part of the network.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on ONAR's current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy, and financial needs. These statements are not historical facts and are inherently uncertain and outside of ONAR's control. Forward-looking statements include, among other things, statements regarding ONAR's expectations regarding its ability to achieve its financial and strategic goals, including surpassing $100 million in revenue and securing a NASDAQ listing; its ability to expand its client base and market share; and its ability to develop and launch new products and services. Actual results may differ materially from ONAR's expectations and projections due to various risks and uncertainties, including market conditions, competition, the ability to protect intellectual property, the ability to manage growth, changes in laws and regulations, and other factors described in ONAR's filings with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and ONAR undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/onar-announces-onar-labs-and-commercialization-of-proprietary-ai-marketing-platform-already-generating-results-across-200m-in-cumulative-client-revenue-302356835.html
$RELT News: ONAR to Present at the 2025 Sequire Investor Summit in Puerto Rico
Los Angeles, CA, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Reliant Holdings, Inc. (OTCQB:RELT), soon to be Onar Holding Corporation, a leading network of specialized marketing agencies and business consultancies, is thrilled to announce its participation in the prestigious Sequire Investor Summit, taking place in Puerto Rico on January 21-23, 2025. This highly anticipated event brings together public companies and forward-thinking investors to explore emerging opportunities and foster meaningful connections.
Representing ONAR at the summit will be CEO Claude Zdanow, who will share his ambitious vision for the company's future. Attendees will gain insights into ONAR's unique approach, which leverages AI and a diverse network of specialized agencies to deliver unparalleled service and results to growth and middle-market businesses.
“We are honored to be part of the Sequire Investor Summit and to share our story with such an esteemed audience of investors and industry leaders,” said Zdanow. “This event provides a platform to showcase our accomplishments and outline our strategic vision as we continue to shape the future of marketing.”
The Sequire Investor Summit is renowned for connecting innovative companies with a diverse network of investors, providing an ideal forum for exchanging ideas and building partnerships. ONAR’s participation underscores its commitment to transparency, growth, and collaboration within the investment community.
Event Details:
Date: January 21-23, 2025
Location: Condado Vanderbilt Hotel in San Juan, Puerto Rico
Presentation Time: Wednesday, January 22, 2025 at 11:00 AM AST
To learn more about the Sequire Investor Summit, please visit https://puertorico.srax.com/
About SRAX
SRAX Inc. is a financial technology company that unlocks data and insights for publicly
traded companies. Through its premier investor intelligence and communications
platform, Sequire, companies can track their investors’ behaviors and trends and use
those insights to engage current and potential investors across marketing channels. For
more information on SRAX, visit srax.com and mysequire.com
About ONAR
ONAR (OTCQB: RELT) is a dynamic marketing and business solutions network, currently publicly traded as Reliant Holdings, Inc. with plans to become Onar Holding Corporation in the near future. ONAR's mission is to provide unparalleled service through an integrated, AI-driven approach, leveraging its diverse brand family's strengths. Committed to honor, candor, and best-in-class results, ONAR aims to lead the industry by example, ensuring every client relationship is deeply rooted in trust and excellence.
ONAR has nearly 50 employees across five continents, and it is aggressively expanding its team to support the company’s growth and acquisition pipeline. Its agencies service over 45 clients across various industries:
Performance Marketing & SEO: Our high-touch performance marketing agency, Storia, specializes in brand growth, data-driven excellence, and paid advertising.
Full-Service Healthcare Marketing: Partnering with healthcare professionals, Of Kos provides the best possible patient experience and strives to revolutionize the standard of care.
Experiential Marketing & Events: CHALK is an experiential marketing powerhouse of event architects who turn bold ideas into unforgettable reality, designing events that dare to defy the ordinary.
ONAR’s network of agencies focuses on servicing companies ranging from $50M to $1B+ in revenue, and ONAR is actively searching for agencies to acquire and become part of the network.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on ONAR's current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy, and financial needs. These statements are not historical facts and are inherently uncertain and outside of ONAR's control. Forward-looking statements include, among other things, statements regarding ONAR's expectations regarding its ability to achieve its financial and strategic goals, including surpassing $100 million in revenue and securing a NASDAQ listing; its ability to expand its client base and market share; and its ability to develop and launch new products and services. Actual results may differ materially from ONAR's expectations and projections due to various risks and uncertainties, including market conditions, competition, the ability to protect intellectual property, the ability to manage growth, changes in laws and regulations, and other factors described in ONAR's filings with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and ONAR undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Media Contact:
Sara Scully
Marketing Manager
ONAR
213-437-3081
IR@onar.com
$HNOI News: HNO International Targets NASDAQ Uplist and Capital Raise with Respected Investment Banking Firm
HOUSTON, Jan. 14, 2025 /PRNewswire/ -- HNO International, Inc. (OTC: HNOI), a leader in hydrogen-based clean energy technologies, is pleased to announce the next steps in execution of management's NASDAQ plans with a leading Wall Street investment banking firm to assist with its acquisition strategy, sourcing capital, and NASDAQ uplist process.
HNO International has retained the investment banking firm as placement agent and financial advisor for up to $20 million for capital expenditures and future acquisitions through a Reg-A.
The investment banking firm is a full-service broker/dealer, and has been providing services to both public and private companies through IPO's, Pre-IPO-Special Vehicles (SPV), Private Placements, Real Estate Investment Trusts, 1031 Tax Exchange Funds and Special Purpose Acquisition Company (SPAC) opportunities since the early 1980's.
The Managing Director of the Firm, commented "The global demands for energy continue to climb at extraordinary rates, prompting the need for additional sources, of which HNO International is set to play a key role. We feel our extensive service portfolio is a great match, one that will take HNO International from the small OTC market space to a global reach, through additional financing and the NASDAQ uplist."
"From the start, our goal with HNO International was to build a solid, global-reaching, energy supplier, servicer and energy product development company. The recent invite to be interviewed on the NASDAQ floor (see link) along with this announced engagement of the investment banking firm, further confirms the ground work we've done building a strong company with increasing shareholder value has worked. 2025 is going to be another amazing year for the company and shareholders. We look forward to bringing you all the exciting developments we have in store," said Donald Owens, Chairman of the Board of Directors and CEO of HNO International.
Recent NASDAQ floor interview:
$IVDN: Innovative Designs Inc. Reports Record Sales Results to Shareholders
PITTSBURGH, Pa - (NewMediaWire) - December 30, 2024 - Innovative Designs, Inc. (OTC Pink: IVDN) today issues the following letter to shareholders from new CEO Joseph A. Riccelli. This letter covers the Company's fiscal third quarter financial results and forward-looking projections, as well as a discussion of significant events in 2024 and plans for the future.
Key points in this letter include:
2024 Fiscal Third Quarter Revenues More Than Doubled Same Period in 2023.
First Nine Months of Fiscal 2024 Delivered Over a 285% Increase Over 2023.
Accelerating Order Flow and Record Backlog in 2024 vs. No Backlog in 2023.
Increasing Production Capabilities to Meet Rising Demand.
Plans for Investor Conference Call / Shareholders Meeting in the company's 2nd Quarter.
Dear IVDN Shareholders:
As the 2024 calendar year comes to a close, I would like to thank all those who have maintained an investment position and followed the developing Innovative Designs story for the marketing of our unmatched Evacuated (Vacuum) Cell R-6 Insultex House Wrap®. As reported in our latest financial filing, the Company's sales revenues for the fiscal third quarter ending July 31, 2024, reached over $250K, surpassing double the $124K total from the same period in 2023. For the trailing nine months from fiscal Q3 in 2024, revenues reached more than $640K, over a 280% increase over the $223K revenue results in 2023.
The Company's full fiscal year ended on October 31, 2024 and we are currently working to complete this financial report which will present even more rapid sales growth. We can now project a 2024 fiscal year-end total of over $1.2M. After this year-end report is filed, we will hold an investor conference call and shareholder's meeting in the second quarter. Sales growth is also continuing in our fiscal first quarter with the largest backorder for Insultex House Wrap® that the company has ever seen, by far vs. no backlog last year.
A significant catalyst to the surging sales of Insultex House Wrap® has been new government building codes calling for continuous insulation and exterior R-Value requirements which are going into effect across the USA. Insultex House Wrap® has proven to be the best overall solution to these new requirements in terms of performance, cost effectiveness and ease of installation. Insultex House Wrap® delivers all this thanks to its unique and patented vacuum cell structure design. No other product on the market today offers a vacuum cell structure. A vacuum is the best thermal insulation possible and only Insultex® incorporates countless evacuated cells. Insultex® also provides a moisture barrier and other key benefits that make it the best choice for home builders and home remodelers for jobs of any size.
Once a new customer buys Insultex House Wrap®, which is a disruptive technology in the building industry, we are finding that they continue to reorder. Insultex House Wrap® provides a substantial savings for new construction, adding an R-6 moisture barrier membrane that does not need additional insulation boards or other support as competitive products.
With the increasing demand for Insultex House Wrap®, one of our top priorities has become increasing new production to maintain a timely order flow. To this end, we have developed new production resources in the last few months which are now able to deliver higher levels of inventory for customers placing rising orders. As demand grows, we have plans for further manufacturing and production. New marketing programs and additional product certifications are also planned.
Lastly, I would like to address the corporate changes that have taken place at Innovative Designs in the last few months including the installation of myself as the new CEO, a position which I am committed to fully with high expectations. The Board of Directors has asked me to convey their sincere appreciation of my father, former CEO Joesph Riccelli, Sr. He has given the Company over 20 years of dedicated service and strong support, all while overseeing important accomplishments. Prior to stepping down as CEO earlier this year for health and family reasons, Joseph Riccelli, Sr. kept Innovative Designs functioning and developing despite many hardships. He also worked to preserve shareholder value by maintaining a small and manageable share structure which today still totals less than 40 million shares outstanding.
Going forward, we intend to keep our customers and shareholders regularly informed of our progress as we address the vital energy saving needs of the multi-billion dollar homebuilding industry. One of our top priorities will be timely filing on all of our future financial reports. We will also be exploring other marketing opportunities for our unique Insultex® material beyond the building industry. For any shareholders or home building/remodeling professionals who wish to speak to me directly I will be available by phone and email at the contact information below. My family and I, as well as everyone on the Innovative Designs team, wish you all a prosperous 2025 ahead.
Sincerely,
Joseph A. Riccelli, CEO
About Innovative Designs, Inc.
Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest and warmest insulator in the market today. For more information, please visit: http://www.insultexhousewrap.com and http://www.idigear.com
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available at http://www.sec.gov.
CONTACT:
Innovative Designs, Inc.
Joseph A. Riccelli, CEO
412-799-0350
riccellijjr@insultexhousewrap.com
http://www.insultexhousewrap.com
View the original release on www.newmediawire.com
$AVRW News: Avenir Wellness Solutions Announces Global Settlement with Ionic Ventures, Eliminating Convertible Debt
SHERMAN OAKS, CA / ACCESSWIRE / December 16, 2024 / Avenir Wellness Solutions, Inc. ("Avenir" or the "Company") (OTCQB:AVRW), a proprietary broad platform technology beauty and wellness company, today announced that it has reached a global settlement with its current debt holder Ionic Ventures LLC ("Ionic") to resolve all disputes between the parties.
In connection with the settlement, a portion of the outstanding convertible notes with an aggregate carrying value of $8.7 million as of September 30, 2024 will be converted into approximately 8.3 million shares of the Company's common stock at a value of approximately $233 thousand, subject to a leak-out agreement. The remaining amount of convertible notes will be extinguished in exchange for a new 10%/11% two-year note with a principal amount of $2.85 million to be issued to Ionic, inclusive of legal fees Ionic incurred in defending against the lawsuit filed by Avenir in the dispute. The new note will require payment equal to at least 50% of the net proceeds the Company receives if it completes a qualified financing, asset sale or M&A transactions up to the accreted amount of the note, but not later than the two-year anniversary of the issuance of the note. As a result of the extinguishment, the Company is expected to recognize a one-time gain of approximately $5.0 million during the fourth quarter of 2024.
The Company also has withdrawn its lawsuit filed against Ionic in the State of New York in connection with the convertible notes originally issued in 2020. As part of the settlement, Avenir acknowledged that Ionic at all times conducted itself in compliance with the 2020 transaction documents, and the settlement agreement reflects that Ionic admitted to no wrongful conduct in connection with the underlying transaction. For further information on the settlement, please refer to the recently filed Form 8-K.
"Despite building a plant-based wellness and beauty business with very high gross margins the last two full fiscal years, Avenir's total market cap has been severely depressed with the value of the entire company recently totaling less than half of last year's sales. After discussions with our financial advisors, Board of Directors and largest shareholders, we confirmed it is universally believed that the significant outstanding convertible debt is the primary reason why there is a disconnect between Company's market value with its underlying business. Our shareholders were clear that our top priority should be elimination of the convertible debt and the settlement of litigation commenced against Ionic. As such, we have been in active negotiations with Ionic for the past few months and were able to come to terms that we believe are extremely beneficial to the Company and our shareholders," commented Nancy Duitch, Chief Executive Officer of Avenir.
Duitch added, "We are thrilled with this transaction that, together with a bridge financing we are in the process of completing, significantly strengthens our balance sheet and eliminates the overhang our shareholders have cited as the significant obstacle preventing them from increasing their ownership of our stock."
Brendan O'Neil, Ionic's Manager, stated, "From the outset, we denied and we continue to strongly deny the allegations asserted against us in the underlying litigation. Given Avenir's agreement to reimburse us for the attorneys' fees we incurred in defending against those allegations, included in the new note, and its acknowledgement that Ionic complied in all material respects with the controlling agreements relating to the 2020 financing, we concluded that it made good business sense to bring the dispute to a close."
Overall, Avenir Wellness Solutions has never been in a better position to capitalize on the high intrinsic value of our Nutri-Strip products as well as our unique and proprietary skin care formulations. With 17 patents under our control, the highly positive reviews Seratopical Revolution DNA Complex is receiving, and more new products in development, 2025 is setting up to be a growth year for the Company. We look forward to keeping our shareholders informed of our progress, developments and milestones as we move forward.
Company Management will be hosting an investor webcast/call to discuss the settlement agreement and provide an update on the Company on Wednesday, December 18, 2024 at 1:00pm PST / 4:00pm EST. Questions may be submitted prior to the webcast by emailing them to investor@avenirwellness.com. To participate in the webcast, please join us at:
https://us06web.zoom.us/j/83688826398?pwd=NzGBQ928B7m34yGgLPBPLI77BY4lGF.1
Meeting ID: 836 8882 6398
Passcode: 797030
One tap mobile
+16694449171,,83688826398#,,,,*797030# US
+13462487799,,83688826398#,,,,*797030# US (Houston)
About Avenir Wellness Solutions, Inc.
Avenir Wellness (OTCQB: AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems. The technology, which is based on fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property by expanding its product lines utilizing the technology. And, as a vertically integrated platform company, Avenir also looks to partner with or license its IP technology to wellness companies worldwide. For more information visit: www.avenirwellness.com.
About The Sera Labs, Inc.
The Sera Labs, Inc. ("Sera Labs"), a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors with innovative products using cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories beauty, health & wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including opt-in subscriptions, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: www.seralabshealth.com and follow Sera Labs on Facebook and Instagram at @seratopical, as well as on X (Twitter) at @sera_ labs.
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.
Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.
Contacts:
Investor Relations
Hanover International Inc.
E: investor@avenirwellness.com
T: (760) 564-7400
SOURCE: Avenir Wellness Solutions, Inc.
I owned this stock years ago before I stopped buying OTC where I lost much $$$.
$MRPT - MacReport.Net is a financial technology company that provides digital asset management and trading services.
https://www.otcmarkets.com/stock/MRPT/profile
$LLLI News: Lamperd Less Lethal Receives New Order for Crowd Control Aerial Burst Pepper Rounds from Major Police Agency
Source:
https://www.otcmarkets.com/filing/html?id=17982774&guid=TAY-kaxQtUxpJth
SARNIA, ON / November 18, 2024/ Lamperd Less Lethal, Inc. (OTC PINK:LLLI), an innovation leader and manufacturer of advanced security solutions for law enforcement, military and security agencies worldwide, has just received a new order for its versatile 37mm Aerial Burst Pepper Rounds (Model Number PT750AB) from a major North American police agency.
Lamperd Aerial Burst munitions are ideal for unruly crowd control and riot response as they can deliver a potent pepper compound directly above a target area covering 200 square feet with no harmful debris dropped on the crowd. This capability makes Lamperd Aerial Burst Pepper rounds an exceptional tool for police to deal with situations of public unrest in a very effective way with the least risk of harm to anyone involved. Lamperd Less Lethal has developed this important product in conjunction with the University of Western Ontario under the most stringent and well documented research and quality control manufacturing processes.
Barry Lamperd, CEO of Lamperd Less Lethal commented, “Our company has a long history of supplying police agencies all over the world with the very best options in less lethal security products which have always met the highest standards for product quality, reliability and safety. This latest order is another testament to the value and versatility of the Lamperd product line which has helped keep the peace and prevent unnecessary harm in many different countries for decades. We are very proud to be able to state that in all of our company history, no one has ever been killed or even seriously injured by any Lamperd Less Lethal product.”
About Lamperd Less Lethal:
Lamperd Less Lethal, Inc. is a developer, manufacturer and international sales company for advanced less lethal weapons, ammunition and other security products marketed to police, correctional, military and private security forces. The company manufactures and sells over 300 different products including small & large caliber projectile guns, flash-bang devices, pepper spray devices, 12 Gauge, 37mm & 40mm launching systems and a variety of different riot shields. Lamperd also offers advisory services and hands-on training classes run by highly accredited instructors. For more information on Lamperd Less Lethal, Inc. visit: http://www.lamperdlesslethal.com
Contact: Lamperd Less Lethal, Inc.
Barry Lamperd, President & CEO
(519) 344-4445
Email: info@lamperdlesslethal.com or sales@lamperdlesslethal.com
Company Website:
http://www.lamperdlesslethal.com
Lamperd Less Lethal on Facebook:
https://www.facebook.com/lamperdlesslethal
Lamperd Less Lethal on Twitter:
https://www.twitter.com/LLLI_LessLethal
Barry Lamperd on Twitter:
https://www.twitter.com/lamperd_llli
$MRPT - MacReport.Net is a financial technology company that provides digital asset management and trading services.https://www.otcmarkets.com/stock/MRPT/profile
$ILLR Conor McGregor and Tom Brady asked to join forces to bring massive #BKFC event to 30,000-seater soccer stadium!
https://bloodyelbow.com/2024/11/05/conor-mcgregor-and-tom-brady-asked-to-join-forces-to-bring-massive-bkfc-event-to-30000-seater-soccer-stadium/
$LLLI News: Lamperd Less Lethal and NAPC Defense form Joint Venture for Security Products Marketing in The USA and Worldwide
Source:
https://ih.advfn.com/stock-market/USOTC/lamperd-less-lethal-pk-LLLI/stock-news/94797468/form-8-k-current-report
SARNIA, ON / October 29, 2024/ Lamperd Less Lethal, Inc. (OTC PINK:LLLI), an innovation leader and manufacturer of advanced security solutions for law enforcement, military and security agencies worldwide, today announces the signing of a new Master Distributor agreement with NAPC Defense, Inc. (OTC Pink: BLIS). This agreement shall be for sales and distribution of the full Lamperd product line and training services to law enforcement, military and other government authorized agencies in the USA and other countries around the world where NAPC Defense has established customer relations.
NAPC Defense is licensed and approved to broker munitions and military hardware already produced and in inventory at various locations worldwide. NAPC Defense benefits from the ability to bid and win contracts that are set aside in the Defense industry from a vast knowledge of Government Contracting. Another NAPC Defense area of expertise is brokering of munitions and military hardware already produced and in inventory at various locations worldwide, NAPC Defense is brokering multiple munitions and military hardware items that are of interest to Allied and NATO forces in the Ukraine and the Middle East, which also require U.S. State Department approval.
Lamperd Less Lethal has been assigned a NATO Commercial and Government Entity (NCAGE) Code which enables it to sell military supplies to any NATO member country, and a Federal Business Firearms License for the manufacture, repair, storage, import, export and sale of virtually any manner of firearms and ammunition. Lamperd Less Lethal is one of only a very few manufacturers of less-lethal munitions in the world to receive these approvals.
NAPC Defense was founded by a Service Disabled Veteran. Registered with the Directorate of Defense Trade Controls, the company has team members experienced in all areas of ammunition, weapons, platforms, and airframe lifecycle management from mission need through demilitarization. NAPC Defense utilizes a Quality Management philosophy that is derived from ISO 9001:2008. The organization has tailored its philosophy to ensure that Customer quality initiatives are included in our day-to-day business processes. The team members are knowledgeable with all current initiatives related to US military specification ammunition and weapons to include the latest critical safety characteristic control planning and Material Readiness Assessment and Planning initiatives.
The NAPC Defense security products portfolio currently includes: Small Arms Weapons, Ammunition, Visual Augmentation, Jamming Equipment, NIJ Certified Body Armor Cornershot, Zero Click and more. With the signing of the new Lamperd distribution agreement, NAPC Defense will now be able to add the option of Less Lethal solutions to its product offerings which had previously been absent.
Stephen Gurba, President of NAPC Defense stated, “We are exceptionally pleased to have reached an agreement to add the extensive and versatile Lamperd line of less lethal security products to our international marketing catalog. In researching the less lethal field we realized that the Lamperd line offers the widest selection, greatest versatility and highest quality solutions for our USA and global customers to possess a capability to effectively deal with increasing riots and other public order crisis with the lowest risk of harm or death to everyone on both sides. We intend to introduce the Lamperd Less Lethal product line to many prospective customers beginning immediately.”
Barry Lamperd, CEO of Lamperd Less Lethal commented, “Our entire product development, manufacturing, delivery and training staff are ready to support NAPC Defense with our full commitment in swiftly fulfilling all orders that their marketing program brings to us. To ensure the highest quality control and the quickest delivery times, all our manufacturing is done in-house with raw materials obtained from well established local suppliers. The Lamperd management team is also well versed in dealing with government agencies to obtain the necessary permits for the most efficient delivery to clients in every part of the world.”
About Lamperd Less Lethal:
Lamperd Less Lethal, Inc. is a developer, manufacturer and international sales company for advanced less lethal weapons, ammunition and other security products marketed to police, correctional, military and private security forces. The company manufactures and sells over 300 different products including small & large caliber projectile guns, flash-bang devices, pepper spray devices, 12 Gauge, 37mm & 40mm launching systems and a variety of different riot shields. Lamperd also offers advisory services and hands-on training classes run by highly accredited instructors. For more information on Lamperd Less Lethal, Inc. visit: http://www.lamperdlesslethal.com
About NAPC Defense:
NAPC Defense, Inc. is an armament sales and production company, fully licensed in the United States, with exclusive rights to produce and sell CornerShot USA weapons systems in the U.S and Saudi Arabia, in addition to brokering arms and munitions throughout the world all with US State Department approval. Additional smaller weapons platforms, a series of ballistics protection technologies and related products are in development or being finalized for sale. For more information on NAPC Defense, Inc. visit: https://www.napcdefense.com/
This press release contains forward-looking statements relating to Lamperd Less Lethal, Inc. Lamperd Less Lethal, Inc. undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public
the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Contact: Lamperd Less Lethal, Inc.
Barry Lamperd, President & CEO
(519) 344-4445
Email: info@lamperdlesslethal.com or sales@lamperdlesslethal.com
Company Website: http://www.lamperdlesslethal.com
Lamperd Less Lethal on Facebook: https://www.facebook.com/lamperdlesslethal
Lamperd Less Lethal on Twitter: https://www.twitter.com/LLLI_LessLethal
Barry Lamperd on Twitter: https://www.twitter.com/lamperd_llli
$IDVV News: Winners Waygers AI Powered Sports Handicapping Assistant Launched In Beta
Carlsbad, California--(Newsfile Corp. - August 15, 2024) - International Endeavors Corp. (OTC Pink: IDVV) ("IEC"), a technology holdings company announced that its WITech.ai division launched a one of a kind artificial intelligence (AI) powered sports handicapping assistant today.
We are pleased to announce the launch of winnerswaygers.com in a free beta mode today thus expanding our AI's ability into sports handicapping. IEC's WITech division plans to expand the service quickly into a subscription based model featuring all major sports using the popularity of the NFL football and fantasy betting season as a catalyst to make users aware of the service.
The AI is currently used by professional handicappers that helped to develop the tools and datasets for the AI. WITech is transforming the current complex model into a user friendly service that will appeal to all.
Current plans are to launch in phases starting with a beta mode offering users the ability to sign up for the service for free. Upon the start of the NFL season in September 2024 users will begin receiving handicapping information from the AI to assist in their decision making.
Our goal after beta is to launch our paid subscription service featuring an interactive sports handicapping bot in Mid October 2024 along with an expansion into Hockey and Basketball. We will be offering a discount to any users of the beta version who wish to upgrade at that time.
We are planning in Q4 of 2024 to begin charging $77 per league selected, for example NFL, and will offer an all sports league package for $247 per year/season. As previously indicated there will be a discount for beta members. At that time the beta version will become a free weekly newsletter featuring one pick to allow potential paid subscribers to see how the service works. We have been seeing massive interest in this service and feel we will have thousands of subscribers as the paid service gets rolled out.
Winners Waygers spokesperson Marrion Lewis stated, "We are excited offer the service to the mainstream. For far too long only professionals have had access to the complex data used to make more accurate sports bets. We plan to change the game. The NFL is the most popular sport to bet, so it is fitting to use it for our launch. I'm personally rooting for the chiefs, but we'll let the AI decide."
IDVV board member Ray Valdez stated, "This is the first expansion of the company into adult related, and more importantly recession resilient sectors. With the potential of many thousands of subscribers we are looking forward to discussing winners waygers along with other opportunities the company is pursuing shortly."
Winners Waygers Video
https://vimeo.com/999064151?share=copy
Relevant Links
https://www.americangaming.org/resources/economic-impact-of-legalized-sports-betting/
https://www.statista.com/topics/10895/fantasy-sports-in-the-us/#topicOverview
https://www.espn.com/nfl/story/_/id/39469575/americans-expected-bet-231b-super-bowl-lviii
We encourage everyone to follow us.
Twitter
https://twitter.com/IDVVcorp
Website(s)
https://witech.ai
https://IDVVCORP.COM
About Us
International Endeavors Corporation ("IEC") is a technology holdings company.
The Company currently is reporting its financial information on OTCMarkets.
Our filings can be seen at https://www.otcmarkets.com.
Disclaimer
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
International Endeavors Corporation
Phone:833-705-0022
Email: otc@idvvcorp.com
SOURCE: International Endeavors Corporation, Inc.
https://images.newsfilecorp.com/files/10187/220044_9ae4a1780431c9ef_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/220044
SOURCE International Endeavors Corporation
https://api.newsfilecorp.com/newsinfo/220044/130
AFFL will explode to $105.3768, $18.3515, and $16.568 respectively based on its two peer's MV at peak and its Record-High MV!
LOL, even buying its OTC peer (FCCN: Record-High $41.3) at today's high $5.15 = buying AFFL at $13.1402 which is 328.505 Times of current Super-Ridiculous-Low price $0.04! Which means Easy 328-Bagger Giant & Quick Rally here!
LOL, even buying its OTC-CI-tier peer (SSHT: Record-High $4.1) at June's High $0.95 = buying AFFL at $4.2522 which is 106.305 Times of current Super-Ridiculous-Low price $0.04! Which means Easy 106-Bagger Giant & Quick Rally here! Note, SSHT has -$54,256 Deeper Negative Net Asset or Shareholder's Equity Value v.s. AFFL only has -$33,935 Minor Negative Net Asset or Shareholder's Equity Value!
So, AFFL is Super Undervalued now!
AFFL is the Cheapest CLEAN-Shell with the Sought-After FIXED Super Tiny SS and Debt-FREE Excellent Financial Balance Sheet plus Only A Few Millions Shares Minor Float Available For Trading! Which means that this Diamond-In-Rough can Easily and Quickly soar Over 100-Bagger from here with just about A Couple Of Millions shares of Slapping-Volumes...
AFFL is also at Hyper Oversold status based on its Record-High $6.00!
Note, its recent high was $0.089!
With the addition of the new satellite processing facility, the total amount qualified under the provincial program now reaches $20.2 million.$MAXQ $MAXQF@esherifftv @elonmusk@JeffBezos @torybruno @blueorigin @SpaceX @northropgrumman @RocketLab @ulalaunch https://t.co/sm6C48O7h4
— Kennygetup (@kennygetup) June 22, 2024
$AGBA News June 12, 2024
AGBA/Triller $4bn Merger: The Group files its Preliminary Proxy Statement
https://finance.yahoo.com/news/agba-triller-4bn-merger-group-122000311.html
$FAVO - Global Finance's eleventh annual Innovators Awards program celebrates entities across various categories, including banks, companies, and fintechs, that consistently pioneer new paths and develop innovative financial tools.
https://finance.yahoo.com/news/favo-capital-stewards-investment-capital-130500781.html
$SFWJ - announces a new strategic partnership with one of its subsidiaries with a prominent local Colombian company to begin the export of its first crop of CBD buds to Switzerland within the next six months.
https://finance.yahoo.com/news/sfwj-medcana-announces-strategic-partnership-134500645.html
$CATV: Category V Biotech, Inc. Announces Letter of Intent to Acquire Genetic Networks, Expanding into Biotechnology Sector
MIAMI, May 15, 2024 /PRNewswire/ -- 4Cable TV International, Inc. soon to be known as Category V Biotech, Inc. (OTC: CATV) announced today the execution of a Letter of Intent (LOI) to acquire Genetic Networks, LLC (https://geneticnetworks.com/), a leader in applied molecular biology and drug development. Effective May 15, 2024, the LOI signifies Category V Biotech's acquisition of 100% equity interests in Genetic Networks, marking the company's entry into the biotechnology sector of the Cannabis industry and solidifying its position as a fully integrated global leader in this space.
Genetic Networks brings a proprietary platform known as GeneScape™, which facilitates the rapid and unbiased discovery of optimal drug compounds through whole-genome analysis. By integrating functional assays of drug activity and human gene variants, GeneScape™ can identify the most promising targets and compounds for specific diseases, expediting development timelines and reducing costs. This acquisition enables Category V Biotech to expand into the biotech aspect of the Cannabis industry, leveraging Genetic Networks' expertise in accelerating compound discovery and development for pre-clinical and clinical testing.
"We are excited to welcome Genetic Networks into the Category V Biotech family," stated Michael Feldenkrais, CEO of Category V Biotech. "Their state-of-the-art platform and extensive knowledge will be instrumental as we strive to unlock the full potential of Cannabis-based therapeutics. Together, we anticipate bringing novel treatments to patients faster than ever before as regulated FDA products under the new regulatory environment of the United States."
Under the agreement's terms, Category V Biotech will acquire 100% of Genetic Networks. The transaction is expected to conclude in the second quarter of 2024, pending customary closing conditions.
Dr. Gennaro D'Urso, co-founder of Genetic Networks, echoed this enthusiasm, stating, "Category V Biotech shares our dedication to leveraging genetics to revolutionize drug development. By joining forces, we envisage broadening the reach and impact of our platform, ultimately delivering superior medicines to patients in need."
Following the acquisition, Genetic Networks will operate as a wholly owned subsidiary of Category V Biotech, retaining its existing management team and facilities. Category V Biotech plans to leverage Genetic Networks' capabilities across its global Cannabis operations, including cultivation, biotech research, and retail.
This transaction is the culmination of years of discussions, awaiting the right moment for research and development in the United States to create pharmaceutical-grade products using Cannabis. With the recent announcement of the rescheduling of Cannabis from Controlled Substance I to Controlled Substance III, reflecting a change in U.S. policies, the long-awaited strategy can now come to fruition. This shift paves the way for Category V Biotech and Genetic Networks to capitalize on emerging opportunities in the Cannabis industry, driving innovation and advancing therapeutic solutions for patients.
Category V Biotech remains actively engaged in pursuing additional acquisitions in the Cannabis industry as part of its growth strategy, with further transactions expected to be announced in the coming months.
About Genetic Networks, LLC
Genetic Networks, LLC, established in 2015, has been at the forefront of serving three of the top ten bio-pharmaceutical companies with its GeneScape™ technology. GeneScape™ expedites drug asset development through applied molecular biology, offering a multidimensional map of diseases and drugs that integrates genome-wide functional assays of drug activity (H-Tech) and human genes and gene variants (Y-Tech) using proprietary analytics. Genetic Networks' GeneScape™ platform accelerates the discovery and development of optimal candidate compounds for pre-clinical and clinical testing, identifying the optimal intersection between targets and compounds in specific disease spaces through whole-genome genetic perturbation and analysis.
About Category V Biotech, LLC, Inc.
Category V Biotech, LLC, Inc. (OTC: CATV) aims to establish and operate a fully integrated global Cannabis company, encompassing biotech research, cultivation, manufacturing, and retail. Through strategic acquisitions and organic growth, the company strives to emerge as the world's leading provider of pharmaceutical Cannabis- based products and therapies.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements regarding Category V Biotech, LLC's business, which are not historical facts but are based on the company's current beliefs, expectations, and assumptions about its future business, plans, strategies, projections, anticipated events, and trends. Such forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are beyond the company's control. Actual results and financial conditions may differ materially from those indicated in the forward- looking statements due to various factors. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, made from time to time, except as required by law.
SOURCE: 4Cable TV International, Inc a/k/a Category V Biotech, LLC, Inc. (OTC: CATV)
Contact: info@4cabletvint.com, +1 3055289614
Cision View original content:https://www.prnewswire.com/news-releases/category-v-biotech-inc-announces-letter-of-intent-to-acquire-genetic-networks-expanding-into-biotechnology-sector-302146392.html
SOURCE 4Cable TV International, Inc.
$AGBA News May 06, 2024
Empowering Shareholders: AGBA's US$4b Merger with Triller Ushers in New Era of Value Creation
https://finance.yahoo.com/news/empowering-shareholders-agbas-us-4b-130000814.html
$IVDN News on sales surge for superior, energy saving house wrap: Innovative Designs Sales Update
PITTSBURGH, PA- (NewMediaWire) - May 30, 2024 - Innovative Designs, Inc. (OTCQB: IVDN) continues its upward sales trend into the end of May 2024. Year-to-date sales have already surpassed FYE2023 by over 33% with 5 months remaining in FYE2024. The growth is attributed to a substantial increase in the number of new retailers that are now carrying the company's Insultex House Wrap®. As new energy codes are implemented across the United States, homebuilders/contractors are using Insultex House Wrap® as a convenient R-Value continuous insulation to a wall system.
Our notable growth in sales can be attributed to Built Link Solutions (Formerly Compound Construction) based in Grand Rapids, MI. Built Link Solutions is working to become the primary source for industry professionals, innovators, and stakeholders to discover, evaluate, and adopt the latest advancements in building materials, tools and technologies. Having curated a comprehensive national distribution network, they bring pioneering solutions like Insultex House Wrap® to market, propelling the evolution of the construction industry towards a future where innovation thrives, and buildings meet the needs of tomorrow. Since coming onboard, Built Link Solutions has:
Established a comprehensive national distribution network to service customers where they are when they need it.
Grown national awareness of product benefits and specifications through their dedicated sales agents and attendance at building industry trade shows across the country.
Conducted in-person sales training and online seminars to educate sales associates on Insultex House Wrap®.
Streamlined the sales process to deliver consistent and superior level service to customers of all sizes and needs.
Implemented volume pricing models and incentive discounts to meet the needs for scale and demand.
As building codes and exterior R-Value requirements are quickly evolving across the country, Built Link Solutions has proven highly proactive in contacting prospective accounts, notifying them of the cost-effective solution that our Insultex House Wrap® provides.
Randy Kimbler, Director of Business Development for Built Link Solutions, commented, "Insultex House Wrap® is gaining traction in the market as it provides a timely and effective solution. Its cost-effectiveness, innovation, and ability to address today's building challenges are driving positive feedback nationwide."
About Innovative Designs, Inc.
Innovative Designs, Inc. manufactures the Insultex® House Wrap and Arctic Armor® Line, under the "i.d.i.gear" label featuring INSULTEX®. Patented INSULTEX® is the thinnest, lightest, and warmest insulator in the market today. For more information, please visit:
http://www.idigear.comorhttp://www.insultexhousewrap.com.
Disclaimer
Certain statements in this press release constitute "forward-looking" statements as defined by federal law. Such statements are based on assumptions, but there is no assurance that actual outcomes will not be materially different as those implied. Any such statements are made in reliance on the "Safe Harbor" protections provided under the Private Securities Reform Act of 1995 and are subject to various factors, including the risks and matters discussed in the Company's SEC filings available athttp://www.sec.gov.
CONTACT:
Innovative Designs, Inc.
Joseph Riccelli, CEO
412-799-0350
joer@idigear.com
http://www.insultexhousewrap.com
Built Link Solutions
Randy Kimbler, Dir. Business Development
616-443-3200
RandyK@Builtlinksolutions.com
News Source: Innovative Designs Inc
$FAVO News January 25, 2024
FAVO Capital, Inc. Opens A Second Call Centre Location in Dominican Republic and Continues to Implement its Growth Strategy
https://finance.yahoo.com/news/favo-capital-inc-opens-second-131500325.html
#favocapital @favocap
$GRLF: Green Leaf Innovations, Inc. Sets Sail for History
Join Cubanacan Heritage at Battleship New Jersey Museum's Annual 'Cigars on the River' Event
PEMBROKE PINES, FL / ACCESSWIRE / May 15, 2024 / Green Leaf Innovations, Inc., (OTC PINK:GRLF), an importer and wholesale distributor of premium hand-rolled cigars, is proud to announce its participation in the highly anticipated 'Cigars on the River' event at the iconic Battleship New Jersey Museum and Memorial.
Overlooking the majestic Delaware River and the breathtaking Philadelphia skyline, this annual soirée promises an unforgettable evening of indulgence and philanthropy. Guests will savor the finest cigars, exquisite cuisine, and handcrafted cocktails amidst the historic setting of the Battleship New Jersey.
Cubanacan Heritage, a cornerstone of Green Leaf Innovations, Inc.'s esteemed portfolio, will take center stage at this prestigious event, showcasing the rich heritage and unrivaled craftsmanship behind each meticulously hand-rolled cigar.
About Battleship New Jersey Museum and Memorial: The Battleship New Jersey Museum and Memorial stands as a testament to our nation's military prowess and enduring legacy. From its storied past in World War II to its pivotal role in modern naval history, the battleship offers a captivating glimpse into the triumphs and sacrifices of our armed forces. Immerse yourself in a journey through time and honor the heroes who have served our country with courage and valor.
Don't miss this exclusive opportunity to join Green Leaf Innovations, Inc. and Cubanacan Heritage aboard the Battleship New Jersey for an evening of camaraderie, celebration, and support for a noble cause.
About Green Leaf Innovations, Inc.
Green Leaf Innovations, Inc., a Florida corporation, is an emerging growth company engaged in the Marketing and Distribution of handmade premium cigars. The company strategically imports and exclusively distributes some of the best known premium cigar brands in the Market created by the Mederos family a Third generation Cigar maker with Robert Mederos at the helm who has owned and operated handmade cigar operation in Nicaragua and the US for over 20 years with a rich family history in the craft dating back to the 1800s Cuba, brands such as CUBANACAN, MEDEROS and TABACALERA SERRANO. In addition to it the company also distributes packaged whole leaf Tobacco to cigar lounges, smoke shops, C-stores and vape shops across the United States and soon International Markets.
Additional information can be found on our websites http://www.greenleafinnovation.com or follow us on Twitter @otcgrlf.
For more information, press only:
PR Contact Name: Ryan Medico
Phone number: (800) 303-6268
Email: info@greenleafinnovation.com
Safe Harbor Statement:
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. The Company may also make written or oral forward-looking statements in its filings with the U.S. Securities and Exchange Commission, in press releases and other written materials, and in oral statements made by its officers, directors or employees to third parties. There can be no assurance that such statements will prove to be accurate. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the Company's Annual Reports on Form 10-K and its other filings with the Securities and Exchange Commission. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control. The Company does not undertake any obligation to update publicly or to revise any statements in this release, whether as a result of new information, future events, or otherwise.
SOURCE: Green Leaf Innovations, Inc.
Awesome News from $RENB!
$RENB - unveils Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward in the fight against cancer.
https://finance.yahoo.com/news/transforming-cancer-detection-renovarocube-introduces-150000564.html
$TWST
$IVDN: On track for a record sales and revenue growth year in 2024, as detailed in the latest company news below. IVDN management is making strong and steady progress to grow market share and also protect the very valuable patent rights of its unique Insultex product line which is the only evacuated cell insulation on the market with energy saving performance that no competitor can match.
IVDN is now starting to see accelerating sales success as word is spreading about Insultex House Wrap as described on the dedicated website at http://www.insultexhousewrap.com. Add to this advantage, the fact that the IVDN product meets or exceeds new building codes going into effect this year requiring continuous insulation while competitors are failing this critical criteria.
Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html
World International Patent Organization (WIPO) Application Accepted on Superior Insulation Advancement to Maximize Global Marketing Opportunities for Innovative Designs, Inc.
Dec. 27, 2023
https://www.newmediawire.com/news/world-international-patent-organization-wipo-application-accepted-on-superior-insulation-advancement-to-maximize-global-marketing-opportunities-for-innovative-designs-inc-7071640
LIG Assets, Inc. Announces Agreement With Insultex House Wrap
October 30, 2023
https://www.globenewswire.com/en/news-release/2023/10/30/2769422/0/en/LIG-Assets-Inc-Announces-Agreement-With-Insultex-House-Wrap.html
Innovative Designs Inc. Receiving Orders From Numerous New Client Accounts for Top Performing Insultex House Wrap With Unmatched R-6 Insulation Value
October 26, 2023
https://www.globenewswire.com/news-release/2023/10/26/2767843/0/en/Innovative-Designs-Inc-Receiving-Orders-From-Numerous-New-Client-Accounts-for-Top-Performing-Insultex-House-Wrap-With-Unmatched-R-6-Insulation-Value.html
Innovative Designs Adds New Accounts
October 2, 2023
https://www.globenewswire.com/news-release/2023/10/02/2752606/0/en/Innovative-Designs-Adds-New-Accounts.html
$RENB News: Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics
LOS ANGELES and AMSTERDAM, April 30, 2024 (GLOBE NEWSWIRE) -- RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (Nasdaq: RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward in the fight against cancer.
Traditional cancer detection methods often fall short in identifying cancers at an early stage when treatment is the most effective. However, Flamingo has the potential to overcome these limitations by harnessing the power of AI to analyze minute amounts of cfDNA data that is highly accurate.
"At RenovaroCube, we believe in pushing the boundaries of possibility," states Daan Vessies, senior scientist at RenovaroCube. "Flamingo undescores our commitment to change cancer diagnostics in a transformative way, ultimately offering clinicians a powerful tool to detect cancer across diverse omic layers."
The Company believes that no single model or molecular modality will reach the requisite sensitivity and specificity throughout the entire patient journey for personalized, precision medicine, from early detection, to predicting the effectiveness of various treatment options, to monitoring the response to therapy within days of starting it, to detecting recurrence at the earliest possible moment. Therefore, our AI/machine learning platform, The Cube, integrates multi-omic data, offering a uniquely comprehensive approach to cancer detection by leveraging a library of trained models for multiple omic layers. One such model Flamingo focuses on is the detection of cancer from ultra-low pass whole genome sequencing (ULP-WGS) cfDNA data using fragmentomics.
Flamingo's development marks a significant milestone in the quest for early cancer detection with RenovaroCube’s engine. By utilizing as few as only 200,000 cell-free DNA fragments per sample, integrating fragment lengths, sequence motifs and employing a meticulously designed neural network, Flamingo achieves remarkable performance in distinguishing cancer from healthy samples.
By augmenting The Cube's arsenal of models operating across various omic layers, Flamingo contributes to the development of non-invasive diagnostics to detect cancer early, enabling timely interventions and improving patient outcomes.
"Adding Flamingo to our Cube will accelerate our efforts to realize a paradigm shift in cancer detection," affirms Frank van Asch, CTO, RenovaroCube. "With its introduction, we are one step closer to realizing our vision of a world where cancer is detected and treated swiftly, saving countless lives in the process."
RenovaroCube invites interested doctors and scientists from international research institutions, clinical cancer centers and all stakeholders to join in the early research use application of our AI/machine learning platform to advance cancer diagnostics and pave the way for a healthier future.
About Renovaro:
Please see a recent interview with Avram Miller, Member of, and Advisor to, the Board of Directors, former co-founder of Intel Capital and SVP of Business Development for Intel:
https://techbullion.com/avram-miller-talks-ab...es-with-ai
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes RenovaroBio, with its advanced cell-gene immunotherapy company, and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.
https://www.renovarogroup.com
https://www.renovarobio.com
https://www.renovarocube.com
About Cyclomics:
Cyclomics is a Dutch company founded in 2018, winner of the Health Holland Venture Challenge (startup of the year) by scientists of the UMC Utrecht. Its ambition is to transform cancer care by enabling faster and more reliable diagnoses, particularly in the context of cancer recurrence thanks to its proprietary circulating tumor DNA (ctDNA) detection technology.
https://www.cyclomics.com/
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
$PDGO - As previously reported a Letter of Intent was signed to acquire 100% interest in 58 oil and gas wells including 12 producing oil and gas wells, and inclusive of the 600 acres of land where the wells are located.
https://www.otcmarkets.com/stock/PDGO/news/Paradigm-Oil-and-Gas-Inc-announces-its-plans-going-forward?id=436241
$IQST is one of the best stocks to buy now in April 2024!
$PDGO - In connection with the previously announced change in control, the new management of PDGO has commenced the process of identifying and initiating targeted acquisitions for PDGO.
https://www.otcmarkets.com/stock/PDGO/news/Paradigm-Oil-and-Gas-Inc-announces-its-plans-going-forward?id=436241
$TKMO Tekumo Inc LOW OS and genuine revenue generated company
0.0007
0.00025 (55.56%)
https://www.tekumo.com/about/
$EDXC - Endexx Corporation Embarks on Strategic Transformation: Leadership Evolution and Intensified Focus on HYLA's Market Dominance
https://finance.yahoo.com/news/endexx-corporation-embarks-strategic-transformation-030020439.html
$DTMXF recovering after the dip, trading way over its 10-day average volume.
Audience Discovery
Unearth new audience segments and untapped markets with AnalyticsGPT. Delve deeper than traditional demographics to truly grasp authentic conversations and interests. By focusing on what genuinely matters to people, you can craft campaigns that not only resonate but also tap into a broader, more relevant audience base.
https://www.datametrex.com/analyticsgpt
$RENB - Cyclomics’ 4th generation liquid biopsy genomics platform is a truly “Omni-Omic” blood test ready for AI application
https://finance.yahoo.com/news/cutting-edge-ai-company-gedicube-144600061.html
$BNNHF Matt Warder is an energy, metals, and mining analyst with nearly two decades of experience covering the natural resource and industrial sectors. As founder and CEO of Seawolf Research, a management consultancy and financial analytics firm, he provides consulting services to clients across multiple sectors with a focus on energy, metals, mining, and industrial supply chains.
Followers
|
926
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
216726
|
Created
|
07/22/10
|
Type
|
Free
|
Moderator Trooperstocks | |||
Assistants ProfitScout |
Posts Today
|
0
|
Posts (Total)
|
216726
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |